Did you miss our 2020 Quality Reporting Webinar? Listen to the recording now!

2020 MIPS IA_PSPA_31: Patient Medication Risk Education

Activity ID

IA_PSPA_31

Activity Weighting

High

Subcategory Name

Patient Safety and Practice Assessment

Activity Description

In order to receive credit for this activity, MIPS eligible clinicians must provide both written and verbal education regarding the risks of concurrent opioid and benzodiazepine use for patients who are prescribed both benzodiazepines and opioids. Education must be completed for at least 75 percent of qualifying patients and occur:
(1) at the time of initial co-prescribing and again following greater than 6 months of co- prescribing of benzodiazepines and opioids, or
(2) at least once per MIPS performance period for patients taking concurrent opioid and benzodiazepine therapy.

Validation

Eligible clinicians and groups must provide both written and verbal education regarding the risks of concurrent opioid and benzodiazepine use for patients who are prescribed both benzodiazepines and opioids.

Suggested Documentation

Education must be completed for at least 75 percent of qualifying patients and occur as follows:
1) at the time of initial co-prescribing and again following greater than 6 months of co- prescribing of benzodiazepines and opioids, or
(2) at least once per MIPS performance period for patients taking concurrent opioid and benzodiazepine therapy.

Register with MDinteractive